Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolf Hervé Fridman

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Bulletin Du Cancer|January 7, 2017
Wolf Hervé Fridman
European Journal of Immunology|January 17, 2013
NK cells from pleural effusions are potent antitumor effector cellsMagali Terme, Wolf Hervé Fridman, Eric Tartour
Oncoimmunology|July 4, 2015
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?Guido Kroemer, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|June 22, 2012
The European Academy of Tumor Immunology: Bridging fields, continents and generationsGuido Kroemer, Wolf Hervé Fridman, Catherine Sautès-Fridman, et al.
Oncoimmunology|September 28, 2013
Trial Watch: Immunostimulatory cytokinesErika Vacchelli, Alexander Eggermont, Wolf Hervé Fridman, et al.
Oncoimmunology|June 22, 2012
Trial watch: Chemotherapy with immunogenic cell death inducersErika Vacchelli, Lorenzo Galluzzi, Wolf Hervé Fridman, et al.
Oncoimmunology|April 5, 2014
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyFernando Aranda, Erika Vacchelli, Alexander Eggermont, et al.
Oncoimmunology|May 21, 2013
Trial watch: Chemotherapy with immunogenic cell death inducersErika Vacchelli, Laura Senovilla, Alexander Eggermont, et al.
Frontiers in Immunology|April 10, 2023
Towards a consensus definition of immune exclusion in cancerAnkur Tiwari, Tamas Oravecz, Laura A Dillon, et al.
Oncoimmunology|June 14, 2013
Trial Watch: Adoptive cell transfer for anticancer immunotherapyErika Vacchelli, Alexander Eggermont, Wolf Hervé Fridman, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Bulletin Du Cancer|January 7, 2017
Wolf Hervé Fridman
European Journal of Immunology|January 17, 2013
NK cells from pleural effusions are potent antitumor effector cellsMagali Terme, Wolf Hervé Fridman, Eric Tartour
Oncoimmunology|July 4, 2015
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?Guido Kroemer, Lorenzo Galluzzi, Laurence Zitvogel, et al.
Oncoimmunology|June 22, 2012
The European Academy of Tumor Immunology: Bridging fields, continents and generationsGuido Kroemer, Wolf Hervé Fridman, Catherine Sautès-Fridman, et al.
Oncoimmunology|September 28, 2013
Trial Watch: Immunostimulatory cytokinesErika Vacchelli, Alexander Eggermont, Wolf Hervé Fridman, et al.
Oncoimmunology|June 22, 2012
Trial watch: Chemotherapy with immunogenic cell death inducersErika Vacchelli, Lorenzo Galluzzi, Wolf Hervé Fridman, et al.
Oncoimmunology|April 5, 2014
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyFernando Aranda, Erika Vacchelli, Alexander Eggermont, et al.
Oncoimmunology|May 21, 2013
Trial watch: Chemotherapy with immunogenic cell death inducersErika Vacchelli, Laura Senovilla, Alexander Eggermont, et al.
Frontiers in Immunology|April 10, 2023
Towards a consensus definition of immune exclusion in cancerAnkur Tiwari, Tamas Oravecz, Laura A Dillon, et al.
Oncoimmunology|June 14, 2013
Trial Watch: Adoptive cell transfer for anticancer immunotherapyErika Vacchelli, Alexander Eggermont, Wolf Hervé Fridman, et al.
Pageof 4